Please try another search
For the six months ended 30 June 2016, Provectus Biopharmaceuticals Inc revenues was not reported. Net loss increased 49% to $13.6M. Higher net loss reflects General and administrative increase from $4.5M to $9.1M (expense), Consulting and contracts labour increase of 22% to $3.2M (expense), Gain (loss) on change in fair value of w decrease from $140K (income) to $0K.
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -5.04 | -8.51 | -9.66 | -5.78 |
Net Income | -5.04 | -8.51 | -9.65 | -5.78 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Assets | 10.83 | 16.02 | 20.44 | 26.6 |
Total Liabilities | 1.69 | 1.83 | 4.12 | 2.07 |
Total Equity | 9.14 | 14.18 | 16.32 | 24.53 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -12.92 | -8.05 | -17.41 | -12.45 |
Cash From Investing Activities | -0.01 | -0.01 | ||
Cash From Financing Activities | 3.64 | 3.64 | 14.2 | 13.94 |
Net Change in Cash | -9.29 | -4.42 | -3.21 | 1.49 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review